Treatment of Hemophilia B
- Okay, here's a breakdown of the information provided, organized for clarity.
- * Recombinant Factor 9: This is the preferred method according to the NBDF's MASAC (Medical and Scientific Advisory Council) due to its increased safety.
- * What they are: Antibodies developed by the body against the factor 9 concentrate, essentially neutralizing its effectiveness.
Okay, here’s a breakdown of the information provided, organized for clarity. This covers treatments, risks, and care recommendations for Hemophilia B:
1. Factor 9 Replacement Therapy
* Recombinant Factor 9: This is the preferred method according to the NBDF’s MASAC (Medical and Scientific Advisory Council) due to its increased safety. It’s created using DNA technology and cannot transmit bloodborne viruses (CDC).
* Available Brands:
* Alprolix
* Benefix
* Idelvion (contains albumin)
* Ixinity
* Rebinyn
* Rixubis
* Plasma-Derived Factor 9: (Not explicitly discussed as preferred, implied to be less safe).
2. Potential Complications: Inhibitors
* What they are: Antibodies developed by the body against the factor 9 concentrate, essentially neutralizing its effectiveness.
* Incidence: About 3 in 100 people with Hemophilia B develop inhibitors.
* Detection: requires yearly lab testing, as inhibitors don’t always cause noticeable symptoms.
* Impact: Makes controlling bleeding episodes more tough.
* Cost: Treatment for inhibitors is very expensive (over $1 million/year according to NBDF).
3. Additional Medications
* antifibrinolytics: Used in addition to factor 9 replacement to help stabilize clots.
* Aminocaproic Acid (Amicar): Prevents breakdown of clots.Used for oral bleeding (mouth, after dental work). Must be followed by factor concentrate to form the clot first. Can be taken orally or intravenously.
* Tranexamic Acid (Lysteda): Slows clot breakdown. Used for heavy menstrual bleeding in girls/women 12+.
4. Importance of Hemophilia Treatment Centers (HTCs)
* Advice: The CDC recommends care through an HTC for those undergoing factor 9 replacement therapy.
* Services Provided: Complete care and education related to all aspects of hemophilia.
* Staff: A multidisciplinary team including:
* Hematologists
* Lab Technologists
* Pathologists
* Orthopedists
* Nurses
* Social Workers/Mental Health Professionals
* Physical Therapists
* other bleeding disorder specialists
* Benefits: patients using HTCs have:
* 40% lower risk of death from hemophilia-related complications.
* 40% lower risk of hospitalization.
Let me know if you’d like me to elaborate on any specific aspect of this information!